<?xml version="1.0" encoding="UTF-8"?>
<p>An estimated 10 of the 71 million hepatitis C virus (HCV)‐infected individuals globally live in sub‐Saharan Africa (SSA).
 <xref rid="hep41482-bib-0001" ref-type="ref">1</xref> Despite significant price reductions and increased availability of direct‐acting antiviral (DAA) medications, fewer than 1% of those infected with HCV in SSA have received antiviral treatment.
 <xref rid="hep41482-bib-0002" ref-type="ref">2</xref> Several factors account for the very low treatment rate, including low rates of HCV case findings, limited funding for diagnostics and treatment, undertrained personnel, and the lack of simple, evidence‐based treatment protocols that can be implemented in non‐specialty centers.
</p>
